Bernstein has reaffirmed its 'Buy' rating on Oracle Corporation, setting a price target of $202 amid Oracle's competitive edge in Cloud Infrastructure. Oracle's shares have been consistent in showing impressive performance with growth figures peaking at 5.32% on November 6. It has hit an all-time high of $178.66, backed by robust growth. This has resulted in Oracle's stock outperforming its competitors. Various firms such as the Consolidated Planning Corp and M&G Plc have sold their shares, while Balentine LLC and Consilium Wealth Advisory LLC have purchased new Oracle shares. Notably, Oracle has unveiled its next-gen AI-powered EHR system, revolutionizing healthcare with advanced cloud capabilities, and clinical AI agent enhancing AI-powered clinical intelligence and workflow automation. It has a strong backing of institutional ownership at 44% with shareholders earning 27% CAGR over the last five years. Oracle has also announced the strengthening of IoT offerings with Vodafone's global connectivity solutions. It's Q1 earnings beat expectations with a surge in cloud revenue resulting in share rising up to 13%. Oracle's stock still seen as cheap despite strong results and guidance, and is viewed as a top growth stock for the long-term.
Oracle Corp ORCL News Analytics from Thu, 08 Aug 2024 07:00:00 GMT to Sat, 09 Nov 2024 09:56:58 GMT -
Rating 8
- Innovation 9
- Information 8
- Rumor 3
